{"generic":"Ethinyl Estradiol\/Etonogestrel","drugs":["Ethinyl Estradiol\/Etonogestrel","NuvaRing"],"mono":[{"id":"jv9cs0","title":"Generic Names","mono":"Ethinyl Estradiol\/Etonogestrel"},{"id":"jv9cs1","title":"Dosing and Indications","sub":{"0":{"id":"jv9cs1b4","title":"Adult Dosing","mono":"<ul><li>Use in postmenopausal women is not indicated<\/li><li><b>Contraception:<\/b> 1 ring inserted into vagina by patient and worn continuously for 3 weeks; remove for 1 week; repeat with new ring (regardless if withdrawal bleeding has or has not finished)<\/li><li><b>Contraception:<\/b> when no hormonal contraception was used in the past month, count the first day of menstruation as day 1 and insert the vaginal ring on or prior to day 5, even if bleeding has not finished; an additional method of nonhormonal contraception is recommended until after the first 7 days of continuous ring use<\/li><li><b>Contraception:<\/b> when switching from a combination oral contraceptive, the vaginal ring may be inserted at any time within 7 days after the last combined oral contraceptive tablet and no later than the day that a new cycle of pills would have been started; no alternative contraception is needed<\/li><li><b>Contraception:<\/b> when switching from a progestin-only pill, insert the vaginal ring any day of the month; do not skip any days between the last progestin pill and the first day of the vaginal ring; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin implant, insert the vaginal ring on the same day as implant removal; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin-containing IUD, insert the vaginal ring on the same day as removal of the IUD; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin injection, insert the vaginal ring on the day the next injection would be due; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from any form of progestin-only contraception, an additional method of contraception is recommended for the first 7 days after insertion of the ring<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted within the first 5 days following a first trimester abortion or miscarriage and no additional method of contraception is needed<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted no sooner than 4 weeks after a second trimester abortion or miscarriage<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted no sooner than 4 weeks postpartum in women electing not to breastfeed; if the woman has not yet resumed her period when initiating therapy with the vaginal ring, an additional method of contraception is recommended for the first 7 days<\/li><\/ul>"},"1":{"id":"jv9cs1b5","title":"Pediatric Dosing","mono":"<ul><li>Use before menarche is not indicated<\/li><li><b>Contraception:<\/b> after menarche, 1 ring inserted into vagina by patient and worn continuously for 3 weeks; remove for 1 week; repeat with new ring (regardless if withdrawal bleeding has or has not finished)<\/li><li><b>Contraception:<\/b> when no hormonal contraception was used in the past month, count the first day of menstruation as day 1 and insert the vaginal ring on or prior to day 5, even if bleeding has not finished; an additional method of nonhormonal contraception is recommended until after the first 7 days of continuous ring use<\/li><li><b>Contraception:<\/b> when switching from a combination oral contraceptive, the vaginal ring may be inserted at any time within 7 days after the last combined oral contraceptive tablet and no later than the day that a new cycle of pills would have been started; no back-up contraception is needed<\/li><li><b>Contraception:<\/b> when switching from a progestin-only pill, insert the vaginal ring any day of the month; do not skip any days between the last progestin pill and the first day of the vaginal ring; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin implant, insert the vaginal ring on the same day as implant removal; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin-containing IUD, insert the vaginal ring on the same day as removal of the IUD; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from a progestin injection, insert the vaginal ring on the day the next injection would be due; an additional method of contraception is recommended for the first 7 days after insertion<\/li><li><b>Contraception:<\/b> when switching from any form of progestin-only contraception, an additional method of contraception is recommended for the first 7 days after insertion of the ring<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted within the first 5 days following a first trimester abortion or miscarriage and no additional method of contraception is needed<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted no sooner than 4 weeks after a second trimester abortion or miscarriage<\/li><li><b>Contraception:<\/b> the vaginal ring may be inserted no sooner than 4 weeks postpartum in women electing not to breastfeed; if the woman has not yet resumed her period when initiating therapy with the vaginal ring, an additional method of contraception is recommended for the first 7 days<\/li><\/ul>"},"3":{"id":"jv9cs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},{"id":"jv9cs2","title":"Black Box Warning","mono":"<b>Vaginal (Insert, Extended Release)<\/b><br\/>Women over 35 years old who smoke should not use etonogestrel\/ethinyl estradiol vaginal ring. Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use.<br\/>"},{"id":"jv9cs3","title":"Contraindications\/Warnings","sub":[{"id":"jv9cs3b9","title":"Contraindications","mono":"<ul><li>breast cancer or other estrogen- or progestin-sensitive cancer, current or history<\/li><li>cerebral vascular or coronary artery disease, current or history<\/li><li>diabetes with vascular disease<\/li><li>DVT or pulmonary embolism, current or history<\/li><li>headaches with focal neurological involvement or migraines with aura<\/li><li>hypercoagulopathies, inherited or acquired<\/li><li>hypersensitivity to any component of the product<\/li><li>hypertension, uncontrolled<\/li><li>liver disease or benign or malignant tumors<\/li><li>migraine headaches, in women over age 35<\/li><li>pregnancy<\/li><li>smoking, if over age 35<\/li><li>uterine bleeding, undiagnosed abnormal<\/li><li>valvular heart disease with thrombogenic complications (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation)<\/li><li>thrombotic disease (arterial or venous), high risk<\/li><\/ul>"},{"id":"jv9cs3b10","title":"Precautions","mono":"<ul><li>arterial thromboses (eg, stroke, myocardial infarction) have been reported, especially in presence of other risk factors<\/li><li>angioedema, hereditary; estrogens may induce or exacerbate symptoms<\/li><li>binding globulin (ie, thyroxine, sex hormone, or cortisol) serum concentrations may increase; binding globulin dose adjustment may be required<\/li><li>bleeding irregularities (eg, breakthrough, spotting, or amenorrhea) may occur, especially during first 3 months; exclude pregnancy or malignancy with persistent or severe bleeding<\/li><li>blood pressure, increase; has been reported with combined hormonal contraceptive use; increased risk in older women and prolonged use<\/li><li>cerebrovascular events (eg, thrombotic and hemorrhagic stroke) have been reported with combination hormone contraceptives; greatest risk among women over 35 years of age who are hypertensive and smoke<\/li><li>cervical cancer or intraepithelial neoplasia; combined hormonal contraceptive use may increase risk<\/li><li>cervical or vaginal erosion or ulceration has been reported; avoid use in women with conditions that increase susceptibility<\/li><li>chloasma may occur; increased risk with history of chloasma gravidarum<\/li><li>depression, history of; monitoring recommended; severe symptoms may warrant discontinuation<\/li><li>diabetes (including prediabetic women); decreased glucose tolerance may occur; monitoring recommended<\/li><li>lipid changes, adverse; may occur with combined hormonal contraceptive use; consider alternative treatments in women who have uncontrolled dyslipidemia<\/li><li>hypertriglyceridemia; increased risk for pancreatitis<\/li><li>gallbladder disease; new or worsening, has been reported with combined hormonal contraceptive use; increased risk of recurrence with history of combination hormone contraceptive-associated cholestasis<\/li><li>headaches, new-onset and recurrent, persistent, or severe; evaluation recommended; discontinuation may be warranted<\/li><li>hepatic adenomas and rare cases of hepatocellular carcinoma have been reported with combination hormonal contraceptive use<\/li><li>hepatic dysfunction may occur; treatment interruption may be required; discontinue if jaundice develops<\/li><li>hereditary angioedema; exogenous estrogens may worsen symptoms<\/li><li>immobilization, prolonged; withdraw during and after event<\/li><li>liver dysfunction; drug may be poorly metabolized<\/li><li>migraine, increased frequency or severity; may precede cerebrovascular event; consider discontinuation<\/li><li>postpartum period; increased risk of thromboembolism; do not initiate therapy earlier than 4 weeks following delivery (in women who are not breastfeeding)<\/li><li>retinal thrombosis may occur; discontinue use if symptoms emerge (eg, loss of vision, diplopia, proptosis, papilledema, or retinal vascular lesions)<\/li><li>surgery, elective and associated with high thromboembolism risk; when possible, withdraw at least 4 weeks before through 2 weeks after surgery<\/li><li>toxic shock syndrome has been reported; increased risk with certain barrier contraceptive and tampon use<\/li><li>thromboembolic and thrombotic disease; increased risk with combined hormonal contraceptive use<\/li><li>venous thromboembolic events (VTE) have been reported; greatest risk with first year of combination hormonal contraceptive (CHC) use and after CHC withdrawal for at least 4 weeks<\/li><li>urinary bladder insertion, inadvertent; may occur; consider in patients with new or persistent urinary symptoms who are unable to locate<\/li><\/ul>"},{"id":"jv9cs3b11","title":"Pregnancy Category","mono":"<ul><li>X (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"jv9cs3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding if possible.  May inhibit lactation.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},{"id":"jv9cs4","title":"Drug Interactions","sub":[{"id":"jv9cs4b13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"jv9cs4b14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"jv9cs4b15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"jv9cs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Psychiatric:<\/b>Mood disorder (6.4%)<\/li><li><b>Reproductive:<\/b>Vaginal discharge (5.7%), Vaginitis (13.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Disorder of cardiovascular system, Hypertension<\/li><li><b>Endocrine metabolic:<\/b>Impaired glucose tolerance<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hematologic:<\/b>Arterial thrombosis, Thrombosis of retinal vein, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Adenoma of liver, Decreased liver function, Liver carcinoma<\/li><li><b>Neurologic:<\/b>Headache (11.2%)<\/li><li><b>Reproductive:<\/b>Vaginal ulcer<\/li><\/ul>"},{"id":"jv9cs6","title":"Drug Name Info","sub":{"0":{"id":"jv9cs6b17","title":"US Trade Names","mono":"NuvaRing<br\/>"},"2":{"id":"jv9cs6b19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"jv9cs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jv9cs6b21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"jv9cs7","title":"Mechanism Of Action","mono":"Vaginal: Contraceptive, vaginal-Combination hormonal contraceptives act by suppression of gonadotropins. The primary effect of this action is inhibition of ovulation. Other alterations include changes in the cervical mucus (which increases the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). <br\/>"},{"id":"jv9cs8","title":"Pharmacokinetics","sub":{"0":{"id":"jv9cs8b23","title":"Absorption","mono":"<ul><li>Vaginal: Rapidly absorbed;   <\/li><li>Etonogrestrel- Bioavailability: 100%<\/li><li>Ethinyl estradiol- Bioavailability: 55.6%   <\/li><\/ul>"},"2":{"id":"jv9cs8b25","title":"Metabolism","mono":"Vaginal: Hepatic: via CYP3A4 pathway; Active metabolites: hydroxylated ethinyl estradiol metabolites <br\/>"},"3":{"id":"jv9cs8b26","title":"Excretion","mono":"Vaginal: Biliary, Fecal and Renal<br\/>"},"4":{"id":"jv9cs8b27","title":"Elimination Half Life","mono":"Vaginal: Etonogestrel: 29.3 h; Ethinyl estradiol: 44.7 h    <br\/>"}}},{"id":"jv9cs9","title":"Administration","mono":"<b>Vaginal<\/b><br\/><ul><li>if the vaginal ring is inadvertently expelled or removed, it may be rinsed in cool to lukewarm water and reinserted as soon as possible, at the latest within 3 hours<\/li><li>discard used ring in re-sealable sachet and discard in waste that is out of reach of children or pets; do not flush in toilet<\/li><\/ul>"},{"id":"jv9cs10","title":"Monitoring","mono":"<ul><li>pregnancy prevention indicates efficacy<\/li><li>glucose monitoring; in prediabetic and diabetic women<\/li><li>blood pressure; in women with well-controlled hypertension<\/li><li>depression recurrence; with history of depression<\/li><\/ul>"},{"id":"jv9cs11","title":"How Supplied","mono":"<b>NuvaRing<\/b><br\/>Vaginal Insert, Extended Release: (Ethinyl Estradiol - Etonogestrel) 0.015 MG\/24 HR-0.12 MG\/24 HR<br\/>"},{"id":"jv9cs12","title":"Toxicology","sub":[{"id":"jv9cs12b31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"jv9cs12b32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"jv9cs12b33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},{"id":"jv9cs13","title":"Clinical Teaching","mono":"<ul><li>Recommend additional form of birth control with use of drugs that decrease vaginal ring effectiveness; alternative contraception should continue for 28 days after drug discontinuation.<\/li><li>Instruct patient to report symptoms of serious cardiovascular events such as myocardial infarction, stroke, venous thrombosis, and pulmonary embolism.<\/li><li>Counsel patient to immediately report symptoms of toxic shock syndrome.<\/li><li>Instruct patient to immediately report symptoms of retinal vein thrombosis (eg, unexplained vision loss, proptosis, diplopia).<\/li><li>Tell patient to immediately report jaundice.<\/li><li>Advise patient to report new headaches that are recurrent, persistent, or severe.<\/li><li>Warn patient that drug does not prevent against HIV or other sexually transmitted diseases.<\/li><li>Side effects may include decreased libido, acne, abdominal pain, dysmenorrhea; breast pain, discomfort, or tenderness; vaginal discomfort or discharge; weight gain, nausea or vomiting; device expulsion, discomfort, or foreign body sensation; mood changes (eg, depression, mood swings, affect lability); headache, including migraine, and vaginitis.<\/li><li>Instruct patient to report abnormal vaginal bleeding.<\/li><li>Tell patient to inform healthcare provider of elective surgeries at least 4 weeks before procedures, if possible.<\/li><li>Instruct patient to discontinue use with confirmed pregnancy.<\/li><li>Advise patients with diabetes to report difficulties with glycemic control.<\/li><li>Advise patient to use additional contraception until the ring has been in place for 7 days.<\/li><li>Instruct patient to rinse in cool to lukewarm water and re-insert within 3 hours if the vaginal ring in inadvertently expelled or removed.<\/li><li>Tell patient not to rely on a vaginal diaphragm as a back-up method of contraception, as the ring may interfere with correct placement of the diaphragm.<\/li><li>Instruct patient not to smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>A ring left in place more than 4 weeks may not provide pregnancy protection. Advise patient to check for pregnancy and then insert a new ring if not pregnant. An additional form of contraception is needed until the new ring has been in place for 7 consecutive days.<\/li><li>Advise patient to rule out pregnancy and use alternative contraception other than a diaphragm with the vaginal ring for 7 consecutive days if a ring-free interval extends beyond 1 week.<\/li><\/ul>"}]}